Changing the Course of Lyme Disease

About Us

FlightpathTM Biosciences is a biotechnology company developing novel therapeutics for the treatment of tick-borne diseases

Based on results of a comprehensive high-throughput screen to identify maximally-effective antiobiotics againstĀ Borrelia burgdorferi, Flightpath is developing proprietary oral drugs for the treatment of acute and Post Treatment Lyme Disease (PTLD). Our goal is to be the first company in decades to bring at least one new therapy to market for patients with Lyme disease.

Flightpath has received both venture funding from private investors and philanthropic organizations.